{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:34:10Z","timestamp":1790894050288,"version":"4.1.0"},"reference-count":47,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"25","license":[{"start":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T00:00:00Z","timestamp":1624579200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002949","name":"Government of Jiangsu Province","doi-asserted-by":"crossref","award":["No. BE2018656"],"award-info":[{"award-number":["No. BE2018656"]}],"id":[{"id":"10.13039\/501100002949","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Abnormal glucose metabolism brings out joint inflammation and destruction in rheumatoid arthritis (RA). The aim of this study was to evaluate the potential of circulating hexokinase-2 (HK2) in peripheral blood mononuclear cells (PBMCs) of rheumatoid arthritis (RA) patients.<\/jats:p>\n            <jats:p>PBMCs were obtained from patients with RA or osteoarthritis (OA) and healthy controls (HCs). The expression of HK2 was assessed by quantitative reverse transcription-polymerase chain reaction (qRT-PCR). The C-reactive protein (CRP) level, erythrocyte sedimentation rate (ESR), Calprotectin, rheumatoid factor (RF), anti-cyclic citrullinated peptides (anti-CCP) antibody level and 28-joint Disease Activity Score (DAS28), Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) were measured. Spearman<jats:sup>'<\/jats:sup>s analysis was performed to determine the association between the level of HK2 and clinical characteristics. A receiver operating characteristic (ROC) curve was employed to evaluate the diagnostic value of HK2 in PBMCs. Logistic regression was used to identify risk factors. Sixty-five RA patients, 35 OA patients, and 40 HCs were included in the study.<\/jats:p>\n            <jats:p>HK2 was upregulated in RA and OA patients compared with that in HCs (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.05). The area under the ROC of HK2 for diagnosing RA and OA was 0.808 and 0.640, respectively. In addition, HK2 levels were increased in active RA compared with those in remittent RA (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.03). Furthermore, HK2 correlated positively with the DAS28-ESR (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.001), CDAI (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.02) and SDAI scores (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.02). Moreover, HK2 was independently associated with an increased risk of disease activity (DAS28-ESR&gt;3.2, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.02; CDAI score&gt;10, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.03; SDAI score&gt;11, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.04). Additionally, HK2 positivity was more frequently detected in patients treated with biologic disease-modifying antirheumatic drugs (bDMARDs) than in those not treated with bDMARDs.<\/jats:p>\n            <jats:p>HK2 levels in PBMCs can be considered an ideal biomarker for diagnosing RA and involved in disease activity in RA. Dysregulation of HK2 may participate in the molecular mechanism of RA and could be an attractive selective metabolic target for RA treatment.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000026504","type":"journal-article","created":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T13:43:57Z","timestamp":1624455837000},"page":"e26504","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":16,"title":["Increased hexokinase-2 as a novel biomarker for the diagnosis and correlating with disease severity in rheumatoid arthritis"],"prefix":"10.1097","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7514-1164","authenticated-orcid":false,"given":"Kai-Long","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-Hua","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju-Pu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Ju","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,6,25]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/nature01661","article-title":"Evolving concepts of rheumatoid arthritis","volume":"423","author":"Firestein","year":"2003","journal-title":"Nature"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1002\/1529-0131(200112)44:12<2746::AID-ART461>3.0.CO;2-Z","article-title":"Long-term morbidity, mortality, and economics of rheumatoid arthritis","volume":"44","author":"Wong","year":"2001","journal-title":"Arthritis Rheum"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0049-0172(05)80003-4","article-title":"The value of C-reactive protein measurement in rheumatoid arthritis","volume":"24","author":"Otterness","year":"1994","journal-title":"Semin Arthritis Rheum"},{"key":"R4-20250504","first-page":"512","article-title":"Biomarkers in rheumatoid arthritis","volume":"19","author":"Atzeni","year":"2017","journal-title":"Isr Med Assoc J"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1136\/annrheumdis-2017-211695","article-title":"Calprotectin as a marker of inflammation in patients with early rheumatoid arthritis","volume":"76","author":"Jonsson","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1155\/2013\/726598","article-title":"Rheumatoid factors: clinical applications","volume":"35","author":"Ingegnoli","year":"2013","journal-title":"Dis Markers"},{"key":"R7-20250504","first-page":"466","article-title":"[Anti-cyclic citrullinated peptide antibodies and rheumatoid arthritis]","volume":"58","author":"Hayashi","year":"2010","journal-title":"Rinsho Byori"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"99","DOI":"10.20344\/amp.5477","volume":"28","author":"Pereira","year":"2015","journal-title":"Acta Med Port"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1756-185X.2011.01598.x","article-title":"Glycolysis and rheumatoid arthritis","volume":"14","author":"Chang","year":"2011","journal-title":"Int J Rheum Dis"},{"key":"R10-20250504","first-page":"1239","article-title":"Glucose transport and metabolism in chondrocytes: a key to understanding chondrogenesis, skeletal development and cartilage degradation in osteoarthritis","volume":"17","author":"Mobasheri","year":"2002","journal-title":"Histol Histopathol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1136\/annrheumdis-2018-213103","article-title":"Hexokinase 2 as a novel selective metabolic target for rheumatoid arthritis","volume":"77","author":"Bustamante","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13075-019-1865-3","article-title":"Inhibition of hexokinases holds potential as treatment strategy for rheumatoid arthritis","volume":"21","author":"Song","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/cr.2015.68","article-title":"Metabolic reprogramming in macrophages and dendritic cells in innate immunity","volume":"25","author":"Kelly","year":"2015","journal-title":"Cell Res"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ccr.2013.06.014","article-title":"Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer","volume":"24","author":"Patra","year":"2013","journal-title":"Cancer Cell"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1242\/jeb.00241","article-title":"Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function","volume":"206","author":"Wilson","year":"2003","journal-title":"J Exp Biol"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"4683","DOI":"10.1038\/sj.onc.1209595","article-title":"Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt","volume":"25","author":"Robey","year":"2006","journal-title":"Oncogene"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"vi5","DOI":"10.1093\/rheumatology\/kes279","article-title":"ACR\/EULAR 2010 rheumatoid arthritis classification criteria","volume":"51","author":"Kay","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.medcli.2017.02.025","article-title":"Evaluation of the activity of rheumatoid arthritis in clinical practice. Agreement between self-rated clinimetric evaluation and clinical evaluation with activity indexes: DAS28, CDAI and SDAI","volume":"149","author":"Horta-Baas","year":"2017","journal-title":"Med Clin (Barc)"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1007\/s00296-011-1810-5","article-title":"Increased myeloperoxidase plasma levels in rheumatoid arthritis","volume":"32","author":"Fernandes","year":"2012","journal-title":"Rheumatol Int"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.cyto.2018.10.002","article-title":"Serum free amino acid levels in rheumatoid arthritis according to therapy and physical disability","volume":"113","author":"Urbaniak","year":"2019","journal-title":"Cytokine"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrrheum.2016.1","article-title":"Metabolomics in rheumatic diseases: desperately seeking biomarkers","volume":"12","author":"Guma","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"48","DOI":"10.28991\/SciMedJ-2019-0102-2","article-title":"Increased expression of miR-377-3p in patients with relapsing remitting multiple sclerosis","volume":"1","author":"Khorasgani","year":"2019","journal-title":"SciMedicine J"},{"key":"R23-20250504","first-page":"376","article-title":"Clinical aspects, pathology and pathophysiology of osteoarthritis","volume":"6","author":"Goldring","year":"2006","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"R24-20250504","first-page":"09","author":"Dalmao-Fern\u00e1ndez","year":"2020","journal-title":"Impaired metabolic flexibility in the osteoarthritis process: a study on transmitochondrial cybrids"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"157","DOI":"10.28991\/esj-2019-01178","article-title":"Developing an integrated genomic profile for cancer patients with the use of NGS data","volume":"3","author":"Kosvyra","year":"2019","journal-title":"Emerg Sci J"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1002\/art.39608","article-title":"Critical role of glucose metabolism in rheumatoid arthritis fibroblast-like synoviocytes","volume":"68","author":"Garcia-Carbonell","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrrheum.2016.20","article-title":"Rheumatoid arthritis: could glucose metabolism be a sweet target for RA therapy?","volume":"12","author":"Onuora","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"288","DOI":"10.4103\/0971-5916.195052","article-title":"Performance of the 2010 American College of Rheumatology\/European League against Rheumatism (ACR\/EULAR) criteria for classification of rheumatoid arthritis in an Indian population: an observational study in a single centre","volume":"144","author":"Kedar","year":"2016","journal-title":"Indian J Med Res"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s10067-015-3047-2","article-title":"The amount of citrullinated proteins in synovial tissue is related to serum anti-cyclic citrullinated peptide (anti-CCP) antibody levels","volume":"35","author":"Olivares-Mart\u00ednez","year":"2016","journal-title":"Clin Rheumatol"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1093\/rheumatology\/kex284","article-title":"Rheumatoid factors do not preferentially bind to ACPA-IgG or IgG with altered galactosylation","volume":"56","author":"Falkenburg","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1136\/jim-2019-001097","article-title":"Diagnostic value of the serum Midkine in patients with rheumatoid arthritis","volume":"68","author":"Abdel Ghafar","year":"2020","journal-title":"J Investig Med"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.3389\/fimmu.2019.01743","article-title":"Fibroblast-like synoviocytes glucose metabolism as a therapeutic target in rheumatoid arthritis","volume":"10","author":"de Oliveira","year":"2019","journal-title":"Front Immunol"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1007\/s10067-006-0343-x","article-title":"Effects of rheumatoid factor isotypes on disease activity and severity in patients with rheumatoid arthritis: a comparative study","volume":"26","author":"Ate\u015f","year":"2007","journal-title":"Clin Rheumatol"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1080\/14397595.2019.1583784","article-title":"Anti-cyclic citrullinated peptide antibody titers decrease in rheumatoid arthritis patients treated with tocilizumab: a pilot study","volume":"30","author":"Noguchi","year":"2020","journal-title":"Mod Rheumatol"},{"key":"R35-20250504","first-page":"1245","article-title":"Diagnosis and management of rheumatoid arthritis","volume":"84","author":"Wasserman","year":"2011","journal-title":"Am Fam Physician"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"1242454","DOI":"10.1126\/science.1242454","article-title":"Fueling immunity: insights into metabolism and lymphocyte function","volume":"342","author":"Pearce","year":"2013","journal-title":"Science"},{"key":"R37-20250504","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.cell.2013.05.016","article-title":"Posttranscriptional control of T cell effector function by aerobic glycolysis","volume":"153","author":"Chang","year":"2013","journal-title":"Cell"},{"key":"R38-20250504","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.immuni.2014.12.030","article-title":"The energy sensor AMPK regulates T cell metabolic adaptation and effector responses in vivo","volume":"42","author":"Blagih","year":"2015","journal-title":"Immunity"},{"key":"R39-20250504","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40170-018-0184-5","article-title":"Hexokinase 2 is dispensable for T cell-dependent immunity","volume":"6","author":"Mehta","year":"2018","journal-title":"Cancer & metabolism"},{"key":"R40-20250504","first-page":"e0191533","volume":"13","author":"Varanasi","year":"2018","journal-title":"Hexokinase II may be dispensable for CD4\u200aT cell responses against a virus infection"},{"key":"R41-20250504","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1084\/jem.20110278","article-title":"HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells","volume":"208","author":"Shi","year":"2011","journal-title":"J Exp Med"},{"key":"R42-20250504","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.immuni.2017.02.010","article-title":"Integrative proteomics and phosphoproteomics profiling reveals dynamic signaling networks and bioenergetics pathways underlying T cell activation","volume":"46","author":"Tan","year":"2017","journal-title":"Immunity"},{"key":"R43-20250504","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.exphem.2019.09.023","article-title":"Glycolytic enzyme hexokinase II is a putative therapeutic target in B-cell malignant lymphoma","volume":"78","author":"Nakajima","year":"2019","journal-title":"Exp Hematol"},{"key":"R44-20250504","first-page":"1510","volume":"201","author":"Perrin-Cocon","year":"2018","journal-title":"Toll-like receptor 4-induced glycolytic burst in human monocyte-derived dendritic cells results from p38-dependent stabilization of HIF-1 (and increased hexokinase II expression)"},{"key":"R45-20250504","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/sj.cdd.4402285","article-title":"Akt mediates mitochondrial protection in cardiomyocytes through phosphorylation of mitochondrial hexokinase-II","volume":"15","author":"Miyamoto","year":"2008","journal-title":"Cell Death Differ"},{"key":"R46-20250504","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.vph.2016.05.002","article-title":"Increased aerobic glycolysis is important for the motility of activated VSMC and inhibited by indirubin-3\u2019-monoxime","volume":"83","author":"Heiss","year":"2016","journal-title":"Vascul Pharmacol"},{"key":"R47-20250504","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.3389\/fimmu.2018.01973","article-title":"Inhibition of glycolysis reduces disease severity in an autoimmune model of rheumatoid arthritis","volume":"9","author":"Abboud","year":"2018","journal-title":"Front Immunol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000026504","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T06:06:00Z","timestamp":1746338760000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000026504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,25]]},"references-count":47,"journal-issue":{"issue":"25","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000026504","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,25]]},"assertion":[{"value":"2020-09-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}